Mingzi Tan
Impact in
- Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment
-
- Cancer-related molecular mechanisms research
Papers in
-
- Glycosylation and Glycoproteins Research 3
- S100 Proteins and Annexins 3
- Ubiquitin and proteasome pathways 2
- Oncology 5
- Cancer Immunotherapy and Biomarkers 2
- Co-authors
- Bei Lin (21 shared papers)Juanjuan Liu (19 shared papers)Liancheng Zhu (16 shared papers)Zhenhua Hu (14 shared papers)Jian Gao (10 shared papers)Huiyu Zhuang (10 shared papers)Dawo Liu (8 shared papers)Mingbo Cai (8 shared papers)
- Journals
- International Journal of Molecular Sciences (3 papers)Tumor Biology (3 papers)Oncotarget (3 papers)Oncology Reports (3 papers)Journal of Experimental & Clinical Cancer Research (2 papers)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Mingzi Tan
27 papers receiving 614 citations
Peers
Comparison fields: 5 of 59
- Reproductive Medicine 107
- Cancer Research 124
- Immunology 139
- Obstetrics and Gynecology 34
- Oncology 109
Countries citing papers authored by Mingzi Tan
This map shows the geographic impact of Mingzi Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingzi Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingzi Tan more than expected).
Fields of papers citing papers by Mingzi Tan
This network shows the impact of papers produced by Mingzi Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingzi Tan. The network helps show where Mingzi Tan may publish in the future.
Co-authors
The 25 scholars most cited alongside Mingzi Tan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 64 | |
| 2 | 2014 | 58 | |
| 3 | 2014 | 47 | |
| 4 | 2015 | 44 | |
| 5 | 2015 | 43 | |
| 6 | Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. | 2015 | 37 |
| 7 | 2015 | 32 | |
| 8 | 2014 | 31 | |
| 9 | 2014 | 30 | |
| 10 | Lewis Y antigen modified CD47 is an independent risk factor for poor prognosis and promotes early ovarian cancer metastasis. | 2015 | 28 |
| 11 | 2014 | 27 | |
| 12 | 2015 | 20 | |
| 13 | 2016 | 18 | |
| 14 | 2013 | 17 | |
| 15 | 2020 | 17 | |
| 16 | 2020 | 16 | |
| 17 | 2017 | 15 | |
| 18 | 2017 | 14 | |
| 19 | 2014 | 14 | |
| 20 | 2015 | 11 |
About Mingzi Tan
Mingzi Tan is a scholar working on Molecular Biology, Oncology, Immunology, Reproductive Medicine and Cancer Research, having authored 28 papers that have together received 619 indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (4 papers), Glycosylation and Glycoproteins Research (3 papers), S100 Proteins and Annexins (3 papers), Autophagy in Disease and Therapy (3 papers), Galectins and Cancer Biology (2 papers), Ubiquitin and proteasome pathways (2 papers), Advanced Glycation End Products research (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Reproductive Medicine (107 citations), Cancer Research (124 citations), Immunology (139 citations), Obstetrics and Gynecology (34 citations) and Oncology (109 citations). Mingzi Tan has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Bei Lin, Juanjuan Liu, Liancheng Zhu, Zhenhua Hu, Jian Gao, Huiyu Zhuang, Dawo Liu, Mingbo Cai, Yingying Hao and Huimin Wang. Their work appears in journals such as International Journal of Molecular Sciences, Tumor Biology, Oncotarget, Oncology Reports and Journal of Experimental & Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.